# BR.31 (NCT02273375)

> Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: completely resected early-stage non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02273375
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Canadian Cancer Trials Group
- Conditions: Non-Small Cell Lung Cancer
- Interventions: MEDI4736; Placebo
- Enrollment: 1415
- Primary outcome: Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements

## Indexed commentary on BR.31 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 33
- Podcasts: 17
- YouTube: 13

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=br-31-nct02273375

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02273375", "email": "<work email>"}; the inbox owner confirms by the emailed link.